LY3023414
Showing 1 - 13 of 13
Triple Negative Breast Cancer Trial in Dallas (Drug 1: LY3023414; Drug 2: Prexasertib)
Active, not recruiting
- Triple Negative Breast Cancer
- Drug 1: LY3023414; Drug 2: Prexasertib
-
Dallas, TexasBaylor University Medical Center
Jul 18, 2022
Endometrial Cancer, Recurrent Endometrial Cancer Trial in United States (LY3023414)
Completed
- Endometrial Cancer
- Recurrent Endometrial Cancer
- LY3023414
-
Basking Ridge, New Jersey
- +5 more
Sep 13, 2022
Prostate Cancer Metastatic Trial in United States (LY3023414, Enzalutamide, Placebo)
Completed
- Prostate Cancer Metastatic
- LY3023414
- +2 more
-
Homewood, Alabama
- +35 more
Apr 17, 2021
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +32 more
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +124 more
Aug 24, 2022
Carcinoma, Non-small Cell Lung Trial in Spain, United States (Abemaciclib, Pemetrexed, Gemcitabine)
Completed
- Carcinoma, Non-small Cell Lung
- Abemaciclib
- +5 more
-
Fayetteville, Arkansas
- +10 more
Aug 22, 2020
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +44 more
- Biopsy
- +23 more
-
Birmingham, Alabama
- +166 more
Feb 2, 2023
Tumor Trial in Chiba, Tokyo (LY3023414)
Completed
- Neoplasm
- LY3023414
-
Chiba, Japan
- +1 more
Jul 20, 2018
Pancreatic Ductal Adenocarcinoma Trial in Worldwide (Abemaciclib, LY3023414, Gemcitabine)
Completed
- Pancreatic Ductal Adenocarcinoma
- Abemaciclib
- +3 more
-
New Haven, Connecticut
- +31 more
Nov 6, 2019
Healthy Trial in Daytona Beach (LY3023414 Reference Fasted, LY3023414 Test Fasted, LY3023414 Test Fed)
Completed
- Healthy
- LY3023414 Reference Fasted
- +2 more
-
Daytona Beach, FloridaCovance Clinical Research Inc
Nov 3, 2016